Format
Sort by

Send to

Choose Destination

Search results

Items: 6

1.

The efficacy and safety of either infliximab or adalimumab in 362 patients with anti-TNF-α naïve Crohn's disease.

Narula N, Kainz S, Petritsch W, Haas T, Feichtenschlager T, Novacek G, Eser A, Vogelsang H, Reinisch W, Papay P.

Aliment Pharmacol Ther. 2016 Jul;44(2):170-80. doi: 10.1111/apt.13671. Epub 2016 May 26.

PMID:
27226407
2.

Interventional closure of atrial septal defects without fluoroscopy in adult and pediatric patients.

Schubert S, Kainz S, Peters B, Berger F, Ewert P.

Clin Res Cardiol. 2012 Sep;101(9):691-700. doi: 10.1007/s00392-012-0445-1. Epub 2012 Mar 28.

PMID:
22454137
3.

iLAP: a workflow-driven software for experimental protocol development, data acquisition and analysis.

Stocker G, Fischer M, Rieder D, Bindea G, Kainz S, Oberstolz M, McNally JG, Trajanoski Z.

BMC Bioinformatics. 2009 Nov 26;10:390. doi: 10.1186/1471-2105-10-390.

4.

Blocking heat shock protein-90 inhibits the invasive properties and hepatic growth of human colon cancer cells and improves the efficacy of oxaliplatin in p53-deficient colon cancer tumors in vivo.

Moser C, Lang SA, Kainz S, Gaumann A, Fichtner-Feigl S, Koehl GE, Schlitt HJ, Geissler EK, Stoeltzing O.

Mol Cancer Ther. 2007 Nov;6(11):2868-78.

5.

Selection of RNase-resistant RNAs.

Kainz S, Czaja R, Greiner-Stöffele T, Hahn U.

Handb Exp Pharmacol. 2006;(173):447-55. Review.

PMID:
16594630
6.

Bivalent monoclonal IgY antibody formats by conversion of recombinant antibody fragments.

Greunke K, Spillner E, Braren I, Seismann H, Kainz S, Hahn U, Grunwald T, Bredehorst R.

J Biotechnol. 2006 Jul 13;124(2):446-56. Epub 2006 Feb 21.

PMID:
16490273
Items per page

Supplemental Content

Write to the Help Desk